Viking Therapeutics Releases Q2 2026 Financial Results

AlphaStreet Newsdesk powered by AlphaStreet Intelligence

VKTX|EPS -$1.10 vs -$1.21 est (+9.1%)|Rev $0 vs $0 est|Net Loss $128.0M

Viking Therapeutics, Inc. reported a narrower-than-expected quarterly loss, as the clinical-stage biopharmaceutical company continues developing therapies for metabolic and endocrine disorders without generating revenue. The company posted a basic and diluted net loss per share of $1.10 for the second quarter of 2026, beating analyst expectations by 9.1% as the Street had anticipated a loss of $1.21 per share based on estimates from 16 analysts.

The San Diego-based biotech firm recorded a net loss of $128.0M for the quarter while revenue remained at zero. Viking operates as a pre-commercial company focused on advancing its pipeline through clinical trials rather than marketed products.

Despite beating loss estimates for the quarter, Viking’s financial performance deteriorated on a year-over-year basis. The loss of $1.10 per share widened 89.7% from the $0.58 loss recorded in the same quarter last year, reflecting increased spending as the company progresses its development programs.

Wall Street maintains a broadly positive outlook on Viking’s prospects, with analyst consensus standing at 14 buy ratings, 3 hold ratings, and 0 sell recommendations. The strong buy-side support suggests confidence in the company’s clinical pipeline despite the absence of product revenue and deepening quarterly losses.

This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.